Patents by Inventor Laurence Moore

Laurence Moore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antineoplastic Combinations with m-TOR Inhibitor, Trastuzumab and/or HKI-272
    Publication number: 20230201155
    Abstract: A combination of temsirolimus and trastuzumab in the treatment of cancer is provided. A combination of temsirolimus and HKI-272 is provided. A combination of a trastuzumab and a HKI-272 is also provided. Regimens and kits for treatment of metastatic breast cancer, containing trastuzumab, temsirolimus and/or HKI-272, optionally in combination with other anti-neoplastic agents, or immune modulators are described.
    Type: Application
    Filed: July 22, 2022
    Publication date: June 29, 2023
    Inventors: Laurence Moore, Charles Michael Zacharchuk, Sridhar Krishna Rabindran
  • Antineoplastic Combinations with m-TOR Inhibitor, Trastuzumab and/or HKI-272
    Publication number: 20220354820
    Abstract: A combination of temsirolimus and trastuzumab in the treatment of cancer is provided. A combination of temsirolimus and HKI-272 is provided. A combination of a trastuzumab and a HKI-272 is also provided. Regimens and kits for treatment of metastatic breast cancer, containing trastuzumab, temsirolimus and/or HKI-272, optionally in combination with other anti-neoplastic agents, or immune modulators are described.
    Type: Application
    Filed: December 10, 2021
    Publication date: November 10, 2022
    Inventors: Laurence Moore, Charles Michael Zacharchuk, Sridhar Krishna Rabindran
  • Antineoplastic combinations with mTOR inhibitor, trastuzumab and/or HKI-272
    Patent number: 10729672
    Abstract: A combination of temsirolimus and trastuzumab in the treatment of cancer is provided. A combination of temsirolimus and HKI-272 is provided. A combination of a trastuzumab and a HKI-272 is also provided. Regimens and kits for treatment of metastatic breast cancer, containing trastuzumab, temsirolimus and/or HKI-272, optionally in combination with other anti-neoplastic agents, or immune modulators are described.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: August 4, 2020
    Assignee: Wyeth LLC
    Inventors: Laurence Moore, Charles Zacharchuk, Sridhar K. Rabindran
  • Antineoplastic Combinations with mTOR Inhibitor, Trastuzumab and/or HKI-272
    Publication number: 20120308560
    Abstract: A combination of temsirolimus and trastuzumab in the treatment of cancer is provided. A combination of temsirolimus and HKI-272 is provided. A combination of a trastuzumab and a HKI-272 is also provided. Regimens and kits for treatment of metastatic breast cancer, containing trastuzumab, temsirolimus and/or HKI-272, optionally in combination with other anti-neoplastic agents, or immune modulators are described.
    Type: Application
    Filed: April 24, 2012
    Publication date: December 6, 2012
    Applicant: Wyeth LLC
    Inventors: Laurence Moore, Charles Zacharchuk, Sridhar K. Rabindran
  • ANTINEOPLASTIC COMBINATIONS WITH mTOR INHIBITOR, TRASTUZUMAB, AND/OR HKI-272
    Publication number: 20090297519
    Abstract: A combination of temsirolimus and trastuzumab in the treatment of cancer is provided. A combination of temsirolimus and HKI-272 is provided. A combination of a trastuzumab and a HKI-272 is also provided. Regimens and kits for treatment of metastatic breast cancer, containing trastuzumab, temsirolimus and/or HKI-272, optionally in combination with other anti-neoplastic agents, or immune modulators are described.
    Type: Application
    Filed: August 12, 2009
    Publication date: December 3, 2009
    Applicant: Wyeth
    Inventors: Laurence Moore, Charles Zacharchuk, Sridhar K. Rabindran
  • Antineoplastic combinations of temsirolimus and sunitinib malate
    Publication number: 20070105887
    Abstract: A combination of temsirolimus and sunitinib malate in the treatment of cancer is provided. Also provided are regimens and kits for treatment of renal cell carcinoma, containing temsirolium and sunitinib malate, optionally in combination with other anti-neoplastic or immune modulators.
    Type: Application
    Filed: November 2, 2006
    Publication date: May 10, 2007
    Applicant: Wyeth
    Inventor: Laurence Moore
  • Antineoplastic combinations with mTOR inhibitor,herceptin, and/or hki-272
    Publication number: 20070104721
    Abstract: A combination of temsirolimus and herceptin in the treatment of cancer is provided. A combination of temsirolimus and HKI-272 is provided. A combination of herceptin and HKI-272 is also provided. Regimens and kits for treatment of metastatic breast cancer, containing herceptin, temsirolimus and/or HKI-272, optionally in combination with other anti-neoplastic agents, or immune modulators are described.
    Type: Application
    Filed: November 2, 2006
    Publication date: May 10, 2007
    Applicant: Wyeth
    Inventors: Laurence Moore, Charles Zacharchuk, Sridhar Rabindran
  • Antineoplastic combinations of CCI-779 and rituximab
    Publication number: 20050272758
    Abstract: This invention provides the use of a combination of CCI-779 and rituximab in the treatment of non-Hodgkin's lymphoma.
    Type: Application
    Filed: March 9, 2005
    Publication date: December 8, 2005
    Applicant: Wyeth
    Inventors: Eliel Bayever, Laurence Moore, Matthew Sherman, Lee Allen, Lewis Strauss